AlertEdge.io
Single-Ticker Trade Brief
RVTY — Revvity Report Date: 2026-08-03 19:41 UTC  |  Sector: Health Care  |  Rating:
RISK DISCLAIMER: This is an momentum signal based on MACD and relative strength. Always validate before entering a position.
▲▲ Momentum Leader — MACD Cross + S&P 500 Outperformance

RVTY has a bullish MACD crossover on daily bars and is outperforming the S&P 500 by +28.21% over the past 63 trading days (RVTY +34.04% vs SPY +5.83%).

Ticker
RVTY
Entry Price
$116.0
vs S&P 500 (63d)
+28.21%
Ticker Return
+34.04%
Stop Loss
$109.02
TP1 Target
$126.46
TP2 Target
$133.43
Risk / Reward
1 : 1.5
Daily ATR stop
View RVTY Chart on TradingView

Key Price Levels

TP1 Target
$126.46
Breakout Level
$0
Entry
$116.0
Stop Loss
$109.02

Fundamentals

P/E Ratio
N/A
EPS (TTM)
N/A
Dividend Yield
0%
52-Wk High
N/A
52-Wk Low
N/A
Beta
N/A

Deep Dive Analysis — Claude Sonnet

RVTY — Revvity | AlertEdge Trade Brief

SETUP

RVTY is closing near session highs at $116.00, breaking out of a $113-114 base on solid momentum. The MACD just crossed bullish on the daily timeframe, confirming the move has legs rather than just being a news spike. More importantly, RVTY is outperforming SPY by 28 points over the past 63 days — this is not a stock catching up to the market, it is a stock leading it. Price is pressing against what appears to be a breakout level with the full candle body holding above the open. Risk is defined at $109.02 with room to TP1 at $126.46 and TP2 at $133.43.

CATALYSTS

Earnings are imminent — reports indicate RVTY is due to release Q2 results within days. Analyst consensus suggests earnings growth is expected. The life sciences tools and diagnostics sector has been quietly recovering as biotech funding stabilizes and pharma R&D spending firms up. Peer action matters here too — Avantor's recent surge on segment stabilization suggests the broader life sciences instrumentation space is finding demand footing. Any beat or raised guidance could accelerate this breakout sharply.

RISKS

Earnings are the primary double-edged sword. A miss or cautious guidance would gut this setup immediately and likely breach the $109 stop. The signal quality score of 50/100 is a real concern — it flags that this entry is not early in the move, meaning the 28% relative strength run may already be priced in. Fundamentals are unavailable, so there is no valuation anchor to lean on. Volume at 86,816 shares is not a surge — it is modest, which means conviction from institutional buyers is not clearly visible yet. The risk/reward at 1:1.5 is below what a pre-earnings setup typically warrants given binary outcome risk.

CONVICTION: Medium — The momentum and relative strength are genuine, but entering directly ahead of earnings with a below-average signal quality score and modest volume limits confidence to a starter position only.

Trade Note: Size down ahead of earnings. If RVTY reports strong results and holds above $116, the signal quality resets and a full position add becomes justified. Do not overcommit to binary event risk here.